


# CORPORATE FACT SHEET




## Corporate Profile:

IntriCon Corporation (NASDAQ: IIN), a medical device company based in Arden Hills, MN, is committed to enhancing the mobility and effectiveness of body-worn devices that connect people to people and to devices around them. IntriCon serves the body-worn device market by designing, developing, engineering, distributing, and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for medical bio-telemetry devices, value hearing health, professional audio communication devices. Over the past several years, IntriCon has increased investments in the continued development of four critical core technologies: Ultra-Low-Power Digital Signal Processing, Ultra-Low-Power Wireless, Microminiaturization, and Miniature Transducers. These four core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable more advanced devices. IntriCon is focused on three key markets: medical, value based hearing healthcare, and professional audio communications. Utilizing this expertise IntriCon is moving to: improve margins by actively increasing the percentage of proprietary content; increase core business revenue and margins by maximizing product research and development; strengthen its leadership position in the body-worn device market by pursuing merger and acquisition opportunities. More information about the company and its products can be found at [www.intricon.com](http://www.intricon.com).

## Revenue & EPS (continuing operation) Quarterly Trends



## TTM Revenue by Market from continuing operations




## Stock Performance:

IIN (Common Stock)	
Exchange	NASDAQ GM (US Dollar)
Price	\$20.00
Volume Change	107%
Volume	28,000
52 Week Range	\$6.05 - \$24.00
Market Cap	\$138,873
EPS from Continuing Rolling Operations	\$0.45
PE Ratio	44
Shares Outstanding	6,943,649

Data as of 03/31/2018

For more up-to-date stock performance information, visit the Investor Relations section of [www.IntriCon.com](http://www.IntriCon.com).



## INVESTOR CONTACT: SCOTT LONGVAL

Chief Financial Officer, Secretary & Treasurer  
 Phone 651-604-9526  
[slongval@IntriCon.com](mailto:slongval@IntriCon.com)

## Recent Events:

March 13, 2018

The Company signed a 5-year lease securing 30,000 square feet of additional manufacturing floor space near its current Arden Hills facility. The added capacity will help the company meet rising demand in the medical business. “The expansion of our medical business, which we expect will continue, warrants this type of investment to fuel the company’s next wave of growth,” said Mark S. Gorder, president and chief executive officer. “The additional space and equipment will enable us to meet rising demand in the near term. The lease also provides for square footage expansion options to meet longer-term anticipated demand increases. We expect to be fully operational in our new facility by mid-2018.”

March 12, 2018

The Company announced that it has completed phase one of the introduction of the NXP® Semiconductor’s NxH2003 Bluetooth Low Energy (BLE) audio streaming SoC into the Companies Lumen™ 155 product family. The Company and NXP’s R&D teams merged exceptional hearing aid engineering and wireless audio streaming semiconductor technology, to deliver hearing aid devices that can stream wireless audio from IntriCon’s wireless accessories, such as remote microphones, consuming only 2.6 mA current at 1.2 Volts, which is exceptional in the industry.

## Financial Update:

May 7, 2018

For the 2018 first quarter, the company reported net sales of \$25.4 million, up 19.6 percent from \$21.2 million in the prior-year period. The increase was primarily due to year-over-year revenue gains from IntriCon’s largest medical customer, and growth in the value-based hearing health direct-to-end-consumer and indirect-to-end-consumer businesses. IntriCon posted net income attributable to shareholders of \$769,000, or \$0.10 per diluted share, versus a net loss attributable to shareholders of (\$270,000), or (\$0.04) per share, for the 2017 first quarter. “Our medical, direct-to-end-consumer and indirect-to-end-consumer value hearing health businesses continue to drive strong top- and bottom-line performance, leading to another quarter of record sales,” said Mark S. Gorder, president and chief executive officer of IntriCon.

### Corporate Governance:

<b>Mark S. Gorder</b>	President, CEO & Founder
<b>J. Scott Longval</b>	CFO, Secretary & Treasurer
<b>Mike Geraci</b>	VP, Sales & Marketing
<b>Dennis Gonsior</b>	VP, Global Operations
<b>Greg Gruenhagen</b>	VP, Quality & Regulatory Affairs

### Corporate Headquarters:

IntriCon Corporation	Tel: 651.636.9770
1260 Red Fox Road	Fax: 651.636.9503
Arden Hills, MN 55112	<a href="http://www.IntriCon.com">www.IntriCon.com</a>